BioLineRx licenses Yissum's leptin antagonist
This article was originally published in Scrip
Executive Summary
The Israeli company BioLineRx has signed a worldwide exclusive licensing agreement with Yissum, the technology transfer company of the Hebrew University of Jerusalem, to develop and commercialise a novel drug candidate to treat inflammatory diseases.